Vycor Medical Inc. Announces First Release of NovaVision®'s Saccadic NeuroEyeCoach™ Therapy

BOCA RATON, FL--(Marketwired - November 07, 2013) - Vycor Medical, Inc. (“Vycor”) (OTCQB: VYCO), a medical device company with a suite of FDA cleared products, announced the first release of its new “direct to the patient” saccadic eye training program to be marketed as NeuroEyeCoach™.

The Company further confirmed that the Internet-based program was on track to be commercially available by year-end 2013. NeuroEyeCoach™ will also be available in an institutional version designed for use at rehabilitation and medical centers. The development work on the institutional version has also been completed.

Commenting on the Company’s announcement, David Cantor, President of Vycor, stated, “Having completed the development of NeuroEyeCoach™, we are on track to have full commercialization and availability of both a retail and institutional rehabilitation product by the end of 2013. We believe that NeuroEyeCoach™ will address a very substantial and under-served market. The retail version of NeuroEyeCoach™ will be available to patients via the Internet allowing for therapy to take place in the comfort of their home. We believe this will be the first such commercially available product offered via the Internet.”

Vycor’s wholly-owned NovaVision® subsidiary is the worldwide leader in the field of vision rehabilitation in the U.S., Europe, and other global markets. In addition to NeuroEyeCoach™, NovaVision® develops and markets a non-invasive, computer-based light stimulation therapy called Vision Restoration Therapy (VRT™). NovaVision’s VRT™ is the only medical device aimed at the restoration of vision for neurologically induced vision loss which has FDA 510(k) clearance to be marketed in the U.S.

The NeuroEyeCoach™ therapy is highly complementary to VRT™. The two therapies address different visual disabilities each of which results from neurologically-induced vision loss -- a loss of visual field as well as difficulty with eye movement, affecting the ability to integrate visual information. VRT provides partial restoration of the patient’s lost visual field. NeuroEyeCoach™ has been specifically developed to increase the efficiency of eye movement and re-train the patients’ ability to integrate visual information between the left and right hand side.

The eventual inclusion of NeuroEyeCoach™ into the patients’ overall therapy regime along with VRT therefore addresses two key visual disabilities and will enable a significant positive impact in a patient’s interaction with their environment and hence their ability to successfully perform their daily living activities.

The Company is in parallel actively working on re-engineering its VRT to also enable it for direct-to-the-patient Internet delivery and to streamline a number of business processes related to the delivery and servicing of patients, although the therapy itself will remain unchanged. Once completed, NovaVision plans to offer both NeuroEyeCoach™ and VRT alongside each other in one therapy suite creating the most robust, affordably available Internet-based visual therapy solution targeted at neurologically induced vision loss.

NeuroEyeCoach™ is a result of collaboration between Vycor management and its world class NovaVision Scientific Advisory Board.

About Vycor Medical, Inc.

Vycor Medical, Inc. (“Vycor”) is dedicated to providing the medical community with innovative and superior surgical and therapeutic solutions and has a growing portfolio of FDA-cleared medical solutions that are changing and improving lives every day. The Company operates two wholly-owned business units: Vycor Medical and NovaVision®, both of which adopt a minimally or non-invasive approach. Both technologies have exceptional sales growth potential, address large potential markets, have the requisite regulatory approvals and are commercialized and generating revenue.

Vycor Medical’s flagship, ViewSite™ Surgical Access Systems (VBAS) is a suite of clear cylindrical minimally invasive disposable devices that hold the potential for speedier, safer and more economical brain surgeries and a quicker patient discharge. VBAS is designed to optimize neurosurgical site access, reduce patient risk, accelerate recovery and add tangible value to the professional medical community. Vycor Medical is ISO 13485:2003 compliant, has FDA 510(k) clearance for VBAS for brain and spine surgeries and regulatory approvals for brain surgeries in Australia, Canada, China, Europe, Japan, Korea and Russia. For an overview of Vycor Medical’s VBAS see http://player.vimeo.com/video/39766887

NovaVision® develops and provides science-driven neurostimulation therapy and other medical technologies that help improve and partially restore sight in patients with neurological vision impairments. The company’s proprietary Visual Restoration Therapy® (VRT) platform is clinically supported to improve lost vision resulting from stroke, traumatic brain injury (“TBI”), or other acquired brain injuries. VRT is the only FDA 510(k) cleared medical device in the U.S. aimed at the restoration of vision for neurologically induced vision loss and can be prescribed by any ophthalmologist, optometrist, neurologist or physiatrist. VRT also has CE Marking for the EU. NovaVision is also developing NeuroEyeCoach™, a new Internet-based “direct to the patient” saccadic eye training program which is expected to be commercially available by year-end 2013. The Company also provides Neuro-Eye Therapy (NeET) in the EU, aimed at increasing visual sensitivity deep within the field defect. For an overview of NovaVision see http://player.vimeo.com/video/39765566

For the latest information on the company, including media and other coverage, and to learn more, please go online at www.vycormedical.com or www.novavision.com.

Safe Harbor Statement

Information in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words “forecast”, “anticipate”, “estimate”, “project”, “intend”, “expect”, “should”, “believe”, and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause Vycor Medical’s actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in Vycor Medical’s filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Vycor Medical herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Vycor Medical disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.